FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128792891> ?p ?o ?g. }

• W3128792891 endingPage "660" @default.
• W3128792891 startingPage "652" @default.
• W3128792891 abstract "•Cobimetinib plus paclitaxel trended toward a numerical increase in progression-free survival and objective response rate.•The triplet combination of atezolizumab, cobimetinib, and taxane did not appear to increase objective response rate.•The triplet combination showed a trend toward improved objective response rate in patients with programmed death-ligand 1 (PD-L1)-positive disease.•These results demonstrate the potential activity of combination immunotherapy for this difficult-to-treat patient subgroup. BackgroundResistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated with upregulation of the mitogen-activated protein kinase (MAPK) pathway. Cobimetinib, an MAPK/extracellular signal-regulated kinase (MEK) inhibitor, may increase sensitivity to taxanes and programmed death-ligand 1 inhibitors. COLET is a three-cohort phase II study evaluating first-line cobimetinib plus chemotherapy, with or without atezolizumab, in patients with locally advanced or mTNBC.Patients and methodsPatients were ≥18 years with locally advanced or mTNBC. Following a safety run-in, patients in cohort I were randomized 1:1 to cobimetinib (60 mg, D3-D23 of each 28-day cycle) or placebo, plus paclitaxel (80 mg/m2, D1, 8, and 15). Additional patients were randomized (1:1) to cohort II or III to receive cobimetinib plus atezolizumab (840 mg, D1 and D15) and either paclitaxel (cohort II) or nab-paclitaxel [cohort III (100 mg/m2, D1, D8, and D15)]. Primary endpoints were investigator-assessed progression-free survival (PFS) (cohort I) and confirmed objective response rate (ORR) (cohorts II/III). Safety and tolerability were also assessed.ResultsIn the expansion stages, median PFS was 5.5 months for cobimetinib/paclitaxel versus 3.8 months for placebo/paclitaxel in cohort I [hazard ratio 0.73; 95% confidence interval (CI) 0.43-1.24; P = 0.25]. In cohort I, ORR was 38.3% (95% CI 24.40-52.20) for cobimetinib/paclitaxel and 20.9% (95% CI 8.77-33.09) for placebo/paclitaxel; ORRs in cohorts II and III were 34.4% (95% CI 18.57-53.19) and 29.0% (95% CI 14.22-48.04), respectively. Diarrhea was the most common grade ≥3 adverse events across all cohorts.ConclusionsCobimetinib added to paclitaxel did not lead to a statistically significant increase in PFS or ORR, although a nonsignificant trend toward a numerical increase was observed. Cobimetinib plus atezolizumab and a taxane did not appear to increase ORR. This demonstrates the potential activity of a combinatorial MEK inhibitor, chemotherapy, and immunotherapy in this difficult-to-treat population. Resistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated with upregulation of the mitogen-activated protein kinase (MAPK) pathway. Cobimetinib, an MAPK/extracellular signal-regulated kinase (MEK) inhibitor, may increase sensitivity to taxanes and programmed death-ligand 1 inhibitors. COLET is a three-cohort phase II study evaluating first-line cobimetinib plus chemotherapy, with or without atezolizumab, in patients with locally advanced or mTNBC. Patients were ≥18 years with locally advanced or mTNBC. Following a safety run-in, patients in cohort I were randomized 1:1 to cobimetinib (60 mg, D3-D23 of each 28-day cycle) or placebo, plus paclitaxel (80 mg/m2, D1, 8, and 15). Additional patients were randomized (1:1) to cohort II or III to receive cobimetinib plus atezolizumab (840 mg, D1 and D15) and either paclitaxel (cohort II) or nab-paclitaxel [cohort III (100 mg/m2, D1, D8, and D15)]. Primary endpoints were investigator-assessed progression-free survival (PFS) (cohort I) and confirmed objective response rate (ORR) (cohorts II/III). Safety and tolerability were also assessed. In the expansion stages, median PFS was 5.5 months for cobimetinib/paclitaxel versus 3.8 months for placebo/paclitaxel in cohort I [hazard ratio 0.73; 95% confidence interval (CI) 0.43-1.24; P = 0.25]. In cohort I, ORR was 38.3% (95% CI 24.40-52.20) for cobimetinib/paclitaxel and 20.9% (95% CI 8.77-33.09) for placebo/paclitaxel; ORRs in cohorts II and III were 34.4% (95% CI 18.57-53.19) and 29.0% (95% CI 14.22-48.04), respectively. Diarrhea was the most common grade ≥3 adverse events across all cohorts. Cobimetinib added to paclitaxel did not lead to a statistically significant increase in PFS or ORR, although a nonsignificant trend toward a numerical increase was observed. Cobimetinib plus atezolizumab and a taxane did not appear to increase ORR. This demonstrates the potential activity of a combinatorial MEK inhibitor, chemotherapy, and immunotherapy in this difficult-to-treat population." @default.
• W3128792891 created "2021-02-15" @default.
• W3128792891 creator A5001032099 @default.
• W3128792891 creator A5010278367 @default.
• W3128792891 creator A5012884004 @default.
• W3128792891 creator A5016481189 @default.
• W3128792891 creator A5024821812 @default.
• W3128792891 creator A5030577122 @default.
• W3128792891 creator A5044108002 @default.
• W3128792891 creator A5044517448 @default.
• W3128792891 creator A5050390394 @default.
• W3128792891 creator A5060585210 @default.
• W3128792891 creator A5071949663 @default.
• W3128792891 creator A5083774265 @default.
• W3128792891 creator A5089319059 @default.
• W3128792891 date "2021-05-01" @default.
• W3128792891 modified "2023-10-16" @default.
• W3128792891 title "A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis" @default.
• W3128792891 cites W1933761723 @default.
• W3128792891 cites W2063432148 @default.
• W3128792891 cites W2096027508 @default.
• W3128792891 cites W2100403180 @default.
• W3128792891 cites W2105660237 @default.
• W3128792891 cites W2114639059 @default.
• W3128792891 cites W2122495232 @default.
• W3128792891 cites W2124427232 @default.
• W3128792891 cites W2131040858 @default.
• W3128792891 cites W2134539328 @default.
• W3128792891 cites W2153017356 @default.
• W3128792891 cites W2163606994 @default.
• W3128792891 cites W2165039236 @default.
• W3128792891 cites W2170602872 @default.
• W3128792891 cites W2289851792 @default.
• W3128792891 cites W2474527756 @default.
• W3128792891 cites W2608811728 @default.
• W3128792891 cites W2612444138 @default.
• W3128792891 cites W2736912049 @default.
• W3128792891 cites W2754588487 @default.
• W3128792891 cites W2792006020 @default.
• W3128792891 cites W2897110470 @default.
• W3128792891 cites W2897422388 @default.
• W3128792891 cites W2919814435 @default.
• W3128792891 cites W2923609917 @default.
• W3128792891 cites W2947477779 @default.
• W3128792891 cites W2984713389 @default.
• W3128792891 cites W2990398119 @default.
• W3128792891 doi "https://doi.org/10.1016/j.annonc.2021.01.065" @default.
• W3128792891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33539944" @default.
• W3128792891 hasPublicationYear "2021" @default.
• W3128792891 type Work @default.
• W3128792891 sameAs 3128792891 @default.
• W3128792891 citedByCount "50" @default.
• W3128792891 countsByYear W31287928912021 @default.
• W3128792891 countsByYear W31287928912022 @default.
• W3128792891 countsByYear W31287928912023 @default.
• W3128792891 crossrefType "journal-article" @default.
• W3128792891 hasAuthorship W3128792891A5001032099 @default.
• W3128792891 hasAuthorship W3128792891A5010278367 @default.
• W3128792891 hasAuthorship W3128792891A5012884004 @default.
• W3128792891 hasAuthorship W3128792891A5016481189 @default.
• W3128792891 hasAuthorship W3128792891A5024821812 @default.
• W3128792891 hasAuthorship W3128792891A5030577122 @default.
• W3128792891 hasAuthorship W3128792891A5044108002 @default.
• W3128792891 hasAuthorship W3128792891A5044517448 @default.
• W3128792891 hasAuthorship W3128792891A5050390394 @default.
• W3128792891 hasAuthorship W3128792891A5060585210 @default.
• W3128792891 hasAuthorship W3128792891A5071949663 @default.
• W3128792891 hasAuthorship W3128792891A5083774265 @default.
• W3128792891 hasAuthorship W3128792891A5089319059 @default.
• W3128792891 hasBestOaLocation W31287928911 @default.
• W3128792891 hasConcept C121608353 @default.
• W3128792891 hasConcept C126322002 @default.
• W3128792891 hasConcept C143998085 @default.
• W3128792891 hasConcept C197934379 @default.
• W3128792891 hasConcept C2775949291 @default.
• W3128792891 hasConcept C2777511904 @default.
• W3128792891 hasConcept C2777701055 @default.
• W3128792891 hasConcept C2778375690 @default.
• W3128792891 hasConcept C2780057760 @default.
• W3128792891 hasConcept C2780110267 @default.
• W3128792891 hasConcept C530470458 @default.
• W3128792891 hasConcept C71924100 @default.
• W3128792891 hasConcept C72563966 @default.
• W3128792891 hasConceptScore W3128792891C121608353 @default.
• W3128792891 hasConceptScore W3128792891C126322002 @default.
• W3128792891 hasConceptScore W3128792891C143998085 @default.
• W3128792891 hasConceptScore W3128792891C197934379 @default.
• W3128792891 hasConceptScore W3128792891C2775949291 @default.
• W3128792891 hasConceptScore W3128792891C2777511904 @default.
• W3128792891 hasConceptScore W3128792891C2777701055 @default.
• W3128792891 hasConceptScore W3128792891C2778375690 @default.
• W3128792891 hasConceptScore W3128792891C2780057760 @default.
• W3128792891 hasConceptScore W3128792891C2780110267 @default.
• W3128792891 hasConceptScore W3128792891C530470458 @default.
• W3128792891 hasConceptScore W3128792891C71924100 @default.
• W3128792891 hasConceptScore W3128792891C72563966 @default.
• W3128792891 hasFunder F4320309432 @default.
• W3128792891 hasIssue "5" @default.

• next